DSpace Community: Publicacions en accés obert derivades de l'activitat investigadora del professorat de la Universitat.
http://hdl.handle.net/2445/7181
Publicacions en accés obert derivades de l'activitat investigadora del professorat de la Universitat.
2024-03-29T08:45:43Z
-
Impact of the COVID-19 pandemic in mortality due to respiratory diseases: A comparative analysis of 2021 and 2020 vs 2019 in Spain.
http://hdl.handle.net/2445/209238
Title: Impact of the COVID-19 pandemic in mortality due to respiratory diseases: A comparative analysis of 2021 and 2020 vs 2019 in Spain.
Author: Soriano, Joan B.; Peláez, Adrián; Fernández Muñoz, Esteve; Ancochea, Julio
Abstract: Introduction: We previously reported an increase in respiratory mortality in 2020 in Spain after COVID-19. It is unclear if this rise is sustained in the longer-term. We aimed to determine whether respiratory mortality in 2021 in Spain returned to pre-pandemic levels. Material and methods: In an observational, large study using official National Institute of Statistics data, we explored deaths due to respiratory diseases, that is, all causes of death by the standard WHO list of diseases of the respiratory system plus COVID-19, tuberculosis and lung cancer. Using the latest available official data of Spain, we analyzed changes in the mortality pattern in Spain from January 2019 to December 2021. We endorsed STROBE guidance for observational research. Results: There were 98,714 deaths due to respiratory diseases in 2021 in Spain, corresponding to 21.9% of all deaths, becoming second in the ranking of causes of death. Respiratory diseases mortality in Spain has not returned to pre-pandemic levels in 2021, still with an increase of 30.3% (95% CI 30.2-30.4) compared to rates in 2019. All respiratory-specific causes of death decreased in 2021, except for lung cancer, that increased in women and decreased in men compared to 2019 (both p<0.05). In a multivariate analysis some established risk factors for respiratory diseases mortality were confirmed, such as male gender and older age; further, an association with reduced mortality in rural Spain was observed, still with a large geographical variability. Conclusions: The COVID-19 pandemic has had a lasting impact on deaths due to respiratory diseases and certain specific causes of death in 2021, and it has disproportionately affected certain regions.
2024-03-27T16:16:41Z
-
The relationship between depressive symptoms, quality of life and miRNAs 8 years after bariatric surgery
http://hdl.handle.net/2445/209237
Title: The relationship between depressive symptoms, quality of life and miRNAs 8 years after bariatric surgery
Author: Martínez-Moreno, Jose M.; Mela, Virginia; Agüera, Zaida; Alvarez-Bermudez, Maria D.; Martín-Reyes, Flores; Granero, Roser; Sánchez-García, Ana; Oliva-Olivera, Wilfredo; Tomé, Monica; Moreno-Ruiz, Francisco J.; Soler-Humanes, Rocío; Fernández-Serrano, Jose L.; Sánchez-Gallegos, Pilar; Sancho-Marín, Raquel; Fernández Aranda, Fernando; García-Fuentes, Eduardo; Tinahones, Francisco J.; Garrido-Sánchez, Lourdes
Abstract: Background: There are conflicting results on whether weight loss after bariatric surgery (BS) might be associated with quality of life (QoL)/depressive symptomatology. We aim to determine whether BS outcomes are associated with QoL/depressive symptomatology in studied patients at the 8-year follow-up after BS, as well as their relationship with different serum proteins and miRNAs. Methods: A total of 53 patients with class III obesity who underwent BS, and then classified into "good responders" and "non-responders" depending on the percentage of excess weight lost (%EWL) 8 years after BS (%EWL ≥ 50% and %EWL < 50%, respectively), were included. Basal serum miRNAs and different proteins were analysed, and patients completed tests to evaluate QoL/depressive symptomatology at 8 years after BS. Results: The good responders group showed higher scores on SF-36 scales of physical functioning, role functioning-physical, role functioning-emotional, body pain and global general health compared with the non-responders. The expression of hsa-miR-101-3p, hsa-miR-15a-5p, hsa-miR-29c-3p, hsa-miR-144-3p and hsa-miR-19b-3p were lower in non-responders. Hsa-miR-19b-3p was the variable associated with the response to BS in a logistic regression model. Conclusions: The mental health of patients after BS is limited by the success of the intervention. In addition, the expression of basal serum miRNAs related to depression/anxiety could predict the success of BS.
2024-03-27T15:34:07Z
-
Intra- and inter-brain synchrony oscillations underlying social adjustment
http://hdl.handle.net/2445/209236
Title: Intra- and inter-brain synchrony oscillations underlying social adjustment
Author: Vicente Guirado, Unai; Ara, Alberto; Marco Pallarés, Josep
Abstract: Humans naturally synchronize their behavior with other people. However, although it happens almost automatically, adjusting behavior and conformity to others is a complex phenomenon whose neural mechanisms are still yet to be understood entirely. The present experiment aimed to study the oscillatory synchronization mechanisms underlying automatic dyadic convergence in an EEG hyperscanning experiment. Thirty-six people performed a cooperative decision-making task where dyads had to guess the correct position of a point on a line. A reinforcement learning algorithm was used to model different aspects of the participants’ behavior and their expectations of their peers. Intra- and inter-connectivity among electrode sites were assessed using inter-site phase clustering in three main frequency bands (theta, alpha, beta) using a two-level Bayesian mixed-effects modeling approach. The results showed two oscillatory synchronization dynamics related to attention and executive functions in alpha and reinforcement learning in theta. In addition, inter-brain synchrony was mainly driven by beta oscillations. This study contributes preliminary evidence on the phase-coherence mechanism underlying inter-personal behavioral adjustment.
2024-03-27T14:40:34Z
-
Hippocampal adaptations in Mild Cognitive Impairment patients are modulated by bilingual language experiences
http://hdl.handle.net/2445/209235
Title: Hippocampal adaptations in Mild Cognitive Impairment patients are modulated by bilingual language experiences
Author: Voits, Tom; Rothman, Jason; Calabria, Marco; Robson, Holly; Aguirre, Naiara; Cattaneo, Gabrielle; Costumero, Víctor; Hernández Pardo, Mireia; Juncadella i Puig, Montserrat; Marín-Marín, Lidón; Suades, Anna; Costa, Albert; Pliatsikas, Christos
Abstract: Bilingualism has been shown to contribute to increased resilience against cognitive aging. One of the key brain structures linked to memory and dementia symptom onset, the hippocampus, has been observed to adapt in response to bilingual experience - at least in healthy individuals. However, in the context of neurodegenerative pathology, it is yet unclear what role previous bilingual experience might have in terms of sustaining integrity of this structure or related behavioral correlates. The present study adds to the limited cohort of research on the effects of bilingualism on neurocognitive outcomes in Mild Cognitive Impairment (MCI) using structural brain data. We investigatewhether bilingual language experience (operationalized as language entropy) results in graded neurocognitive adaptations within a cohort of bilinguals diagnosed with MCI. Results reveal a non-linear effect of bilingual language entropy on hippocampal volume, although they do not predict episodic memory performance, nor age ofMCI diagnosis.
2024-03-27T14:37:18Z
-
EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci
http://hdl.handle.net/2445/209234
Title: EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci
Author: Hidalgo-Tenorio, Carmen; Sadyrbaeva-Dolgova, Svetlana; Enríquez-Gómez, Andrés; Muñoz, Patricia; Plata-Ciezar, Antonio; Miró Meda, José M.; Alarcón, Aristides de; Martínez-Marcos, Francisco Javier; Loeches, Belén; Escrihuela Vidal, Francesc; Vinuesa, David; Herrero, Carmen; Boix Palop, Lucía; Arenas, María del Mar; García Vázquez, Elisa; Arnáiz de las Revillas, Francisco; Pasquau, Juan; EN-DABALCEN study group
Abstract: Objectives: Infective endocarditis (IE) has high mortality and morbidity and requires long hospital stays to deliver the antibiotic treatment recommended in clinical practice guidelines. We aimed to analyse the health outcomes of the use of dalbavancin (DBV) in the consolidation treatment of IEs caused by Gram-positive cocci and to perform a pharmacoeconomic study. Materials and methods: This observational, retrospective, Spanish multicentre study in patients with IE who received DBV as part of antibiotic treatment in consolidation phase were followed for at least 12 months. The study was approved by the Provincial Committee of the coordinating centre. Results: The study included 124 subjects, 70.2% male, with a mean age of 67.4 years and median Charlson index of 4 (interquartile range: 2.5-6). Criteria for definite IE were met by 91.1%. Coagulase-negative staphylococci (38.8%), Staphylococcus aureus (22.6%), Enterococcus faecalis (19.4%), and Streptococcus Spp. (9.7%) were isolated more frequently, all susceptible to vancomycin. Before DVB administration, 91.2% had undergone surgery; 60.5% had received a second regimen for 24.5 d (16.6-56); and 20.2% had received a third regimen for 14.5 d (12-19.5). DBV was administered to facilitate discharge in 95.2% of cases. At 12 months, the effectiveness was of 95.9%, and there was 0.8% loss to follow-up, 0.8% IE-related death, and 3.2% relapse. Adverse events were recorded in 3.2%. The hospital stay was reduced by 14 d, and there was a mean savings of 5548.57 €/patient vs. conventional treatments. Conclusion: DBV is highly effective, safe, and cost-effective as consolidation therapy in patients with IE by Gram-positive cocci, with few adverse events.
2024-03-27T14:24:20Z
-
CoVITEST: A Fast and Reliable Method to Monitor Anti-SARS-CoV-2 Specific T Cells From Whole Blood
http://hdl.handle.net/2445/209233
Title: CoVITEST: A Fast and Reliable Method to Monitor Anti-SARS-CoV-2 Specific T Cells From Whole Blood
Author: Egri N; Olivé V; Hernández-Rodríguez J; Castro P; De Guzman C; Heredia L; Segura AC; Fernández MD; de Moner N; Torradeflot M; Ballus J; Martinez R; Vazquez M; Costa MV; Dobano C; Mazza M; Mazzotti L; Pascal M; Juan M; González-Navarro EA; Calderon H
Abstract: Cellular and humoral immune responses are essential for COVID-19 recovery and protection against SARS-CoV-2 reinfection. To date, the evaluation of SARS-CoV-2 immune protection has mainly focused on antibody detection, generally disregarding the cellular response, or placing it in a secondary position. This phenomenon may be explained by the complex nature of the assays needed to analyze cellular immunity compared with the technically simple and automated detection of antibodies. Nevertheless, a large body of evidence supports the relevance of the T cell's role in protection against SARS-CoV-2, especially in vulnerable individuals with a weakened immune system (such as the population over 65 and patients with immunodeficiencies). Here we propose to use CoVITEST (Covid19 anti-Viral Immunity based on T cells for Evaluation in a Simple Test), a fast, affordable and accessible in-house assay that, together with a diagnostic matrix, allows us to determine those patients who might be protected with SARS-CoV-2-reactive T cells. The method was established using healthy SARS-CoV-2-naïve donors pre- and post-vaccination (n=30), and further validated with convalescent COVID-19 donors (n=51) in a side-by-side comparison with the gold standard IFN-? ELISpot. We demonstrated that our CoVITEST presented reliable and comparable results to those obtained with the ELISpot technique in a considerably shorter time (less than 8 hours). In conclusion, we present a simple but reliable assay to determine cellular immunity against SARS-CoV-2 that can be used routinely during this pandemic to monitor the immune status in vulnerable patients and thereby adjust their therapeutic approaches. This method might indeed help to optimize and improve decision-making protocols for re-vaccination against SARS-CoV-2, at least for some population subsets.Copyright © 2022 Egri, Olivé, Hernández-Rodríguez, Castro, De Guzman, Heredia, Segura, Fernandez, de Moner, Torradeflot, Ballús, Martinez, Vazquez, Costa, Dobaño, Mazza, Mazzotti, Pascal, Juan, González-Navarro and Calderón.
2024-03-27T13:32:20Z
-
Impact of SARS-CoV-2 infection on liver disease
http://hdl.handle.net/2445/209294
Title: Impact of SARS-CoV-2 infection on liver disease
Author: Salgüero Fernández S; Gabriel Medina P; Almería Lafuente A; Ballesteros Vizoso MA; Zamora Trillo A; Casals Mercadal G; Solé Enrech G; Lalana Garcés M; Guerra Ruiz AR; Ortiz Pastor O; Morales Ruiz M
Abstract: Introduction: Abnormal liver biochemistry is not a rare finding in the context of SARS-CoV-2 infection, regardless of patients having pre-existing chronic disease or not Content: This review examines the current body of knowledge on the relationship between COVID-19 and liver injury, which is frequently found in this setting Summary: Although the pathogenesis of liver injury is not fully understood, it has been suggested to be the result of a combination of multiple factors. These include direct injury caused by the virus, immune system hyperactivation, ischemic and drug-induced injury. The prognostic valor of these alterations is also the subject of intense research. Due to their potential impact, these alterations require proper management and treatment, especially in patients with chronic liver disease or liver transplant recipients. Outlook: Some aspects associated with liver injury during COVID-19, especially in severe presentations, are not well understood. Studies assessing the clinical impact of COVID-19 on the healthy or diseased liver may help adjust treatment and immunization guidelines to the profile of the patient. © 2022 Sergio Salgüero Fernández et al., published by De Gruyter, Berlin/Boston.
2024-03-27T13:31:01Z
-
The CBI-R detects early behavioural impairment in genetic frontotemporal dementia
http://hdl.handle.net/2445/209293
Title: The CBI-R detects early behavioural impairment in genetic frontotemporal dementia
Author: Nelson, A; Russell, LL; Peakman, G; Convery, RS; Bouzigues, A; Greaves, CV; Bocchetta, M; Cash, DM; Swieten, JC; Jiskoot, L; Moreno, F; Sanchez del Valle Díaz, Raquel; Laforce, R; Graff, C; Masellis, M; Tartaglia, MC; Rowe, JB; Borroni, B; Finger, E; Synofzik, M; Galimberti, D; Vandenberghe, R; Mendona, A; Butler, CR; Gerhard, A; Ducharme, S; Le Ber, I; Santana, I; Pasquier, F; Levin, J; Otto, M; Sorbi, S; Rohrer, JD
Abstract: Introduction: Behavioural dysfunction is a key feature of genetic frontotemporal dementia (FTD) but validated clinical scales measuring behaviour are lacking at present. Methods: We assessed behaviour using the revised version of the Cambridge Behavioural Inventory (CBI-R) in 733 participants from the Genetic FTD Initiative study: 466 mutation carriers (195 C9orf72, 76 MAPT, 195 GRN) and 267 non-mutation carriers (controls). All mutation carriers were stratified according to their global CDR plus NACC FTLD score into three groups: asymptomatic (CDR = 0), prodromal (CDR = 0.5) and symptomatic (CDR = 1+). Mixed-effects models adjusted for age, education, sex and family clustering were used to compare between the groups. Neuroanatomical correlates of the individual domains were assessed within each genetic group. Results: CBI-R total scores were significantly higher in all CDR 1+ mutation carrier groups compared with controls [C9orf72 mean 70.5 (standard deviation 27.8), GRN 56.2 (33.5), MAPT 62.1 (36.9)] as well as their respective CDR 0.5 groups [C9orf72 13.5 (14.4), GRN 13.3 (13.5), MAPT 9.4 (10.4)] and CDR 0 groups [C9orf72 6.0 (7.9), GRN 3.6 (6.0), MAPT 8.5 (13.3)]. The C9orf72 and GRN 0.5 groups scored significantly higher than the controls. The greatest impairment was seen in the Motivation domain for the C9orf72 and GRN symptomatic groups, whilst in the symptomatic MAPTgroup, the highest-scoring domains were Stereotypic and Motor Behaviours and Memory and Orientation. Neural correlates of each CBI-R domain largely overlapped across the different mutation carrier groups. Conclusions: The CBI-R detects early behavioural change in genetic FTD, suggesting that it could be a useful measure within future clinical trials.
2024-03-27T13:24:46Z
-
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer
http://hdl.handle.net/2445/209292
Title: T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer
Author: Mazzotti, L; Gaimari A; Bravaccini S; Maltoni R; Cerchione C; Juan M; Navarro EA; Pasetto A; Nascimento Silva D; Ancarani V; Sambri V; Calabrò L; Martinelli G; Mazza M
Abstract: The immune system is a dynamic feature of each individual and a footprint of our unique internal and external exposures. Indeed, the type and level of exposure to physical and biological agents shape the development and behavior of this complex and diffuse system. Many pathological conditions depend on how our immune system responds or does not respond to a pathogen or a disease or on how the regulation of immunity is altered by the disease itself. T-cells are important players in adaptive immunity and, together with B-cells, define specificity and monitor the internal and external signals that our organism perceives through its specific receptors, TCRs and BCRs, respectively. Today, high-throughput sequencing (HTS) applied to the TCR repertoire has opened a window of opportunity to disclose T-cell repertoire development and behavior down to the clonal level. Although TCR repertoire sequencing is easily accessible today, it is important to deeply understand the available technologies for choosing the best fit for the specific experimental needs and questions. Here, we provide an updated overview of TCR repertoire sequencing strategies, providers and applications to infectious diseases and cancer to guide researchers' choice through the multitude of available options. The possibility of extending the TCR repertoire to HLA characterization will be of pivotal importance in the near future to understand how specific HLA genes shape T-cell responses in different pathological contexts and will add a level of comprehension that was unthinkable just a few years ago.
2024-03-27T13:22:18Z
-
Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma
http://hdl.handle.net/2445/209232
Title: Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma
Author: Maldonado-Perez, N; Tristan-Manzano, M; Justicia-Lirio, P; Martinez-Planes, E; Munoz, P; Pavlovic, K; Cortijo-Gutierrez, M; Blanco-Benitez, C; Castella, M; Juan, M; Wenes, M; Romero, P; Molina-Estevez, FJ; Maranon, C; Herrera, C; Benabdellah, K; Martin, F
Abstract: Autologous T cells expressing the Chimeric Antigen Receptor (CAR) have been approved as advanced therapy medicinal products (ATMPs) against several hematological malignancies. However, the generation of patient-specific CAR-T products delays treatment and precludes standardization. Allogeneic off-the-shelf CAR-T cells are an alternative to simplify this complex and time-consuming process. Here we investigated safety and efficacy of knocking out the TCR molecule in ARI-0001 CAR-T cells, a second generation alpha CD19 CAR approved by the Spanish Agency of Medicines and Medical Devices (AEMPS) under the Hospital Exemption for treatment of patients older than 25 years with Relapsed/Refractory acute B cell lymphoblastic leukemia (B-ALL). We first analyzed the efficacy and safety issues that arise during disruption of the TCR gene using CRISPR/Cas9. We have shown that edition of TRAC locus in T cells using CRISPR as ribonuleorproteins allows a highly efficient TCR disruption (over 80%) without significant alterations on T cells phenotype and with an increased percentage of energetic mitochondria. However, we also found that efficient TCRKO can lead to on-target large and medium size deletions, indicating a potential safety risk of this procedure that needs monitoring. Importantly, TCR edition of ARI-0001 efficiently prevented allogeneic responses and did not detectably alter their phenotype, while maintaining a similar anti-tumor activity ex vivo and in vivo compared to unedited ARI-0001 CAR-T cells. In summary, we showed here that, although there are still some risks of genotoxicity due to genome editing, disruption of the TCR is a feasible strategy for the generation of functional allogeneic ARI-0001 CAR-T cells. We propose to further validate this protocol for the treatment of patients that do not fit the requirements for standard autologous CAR-T cells administration.
2024-03-27T13:10:43Z